Research programme: infectious disease vaccines - VaxInnate

Drug Profile

Research programme: infectious disease vaccines - VaxInnate

Alternative Names: flagellin.AvHA; flagellin.AvM2e; Hemagglutinin (HA)-based pandemic influenza vaccines - VaxInnate; Hemagglutinin (HA)-based seasonal influenza vaccines - VaxInnate; Human papillomavirus (HPV) vaccine - VaxInnate; Respiratory syncytial virus (RSV) infections - VaxInnate; Swine flu vaccine - VaxInnate

Latest Information Update: 08 Oct 2015

Price : $50

At a glance

  • Originator VaxInnate
  • Class Bacterial vaccines; Influenza A vaccines; Papillomavirus vaccines; Recombinant fusion proteins; Viral vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Clostridium infections; Human papillomavirus infections; Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Respiratory syncytial virus infections

Most Recent Events

  • 08 Oct 2015 Preclinical trials in Clostridium infections in USA (Parenteral)
  • 24 Feb 2011 VaxInnate receives a contract from the Biomedical Advanced Research and Development Authority (BARDA) for development of Recombinant influenza vaccines in USA
  • 13 Jan 2010 Swine flu vaccine licensed to Biological E in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top